

Carbon Reduction Plan

Supplier name

Pharmacosmos UK Ltd

Publication date

17th February 2026

Commitment to achieving net zero

Pharmacosmos A/S is committed to achieving net-zero emissions by 2045. This commitment applies to all affiliates within Pharmacosmos Group, including Pharmacosmos UK Ltd, which is fully owned by Pharmacosmos A/S.

Pharmacosmos UK Ltd. is responsible for the sales and distribution of products within the UK, while product manufacturing is carried out at parent-company level in Denmark at Pharmacosmos A/S. As part of its net-zero commitment, Pharmacosmos A/S is working to reduce emissions associated with the production of medicines. This will also influence the products distributed to the UK market through Pharmacosmos UK Ltd. Hence, parent-level commitment to net zero is vital for the Pharmacosmos UK Ltd's net zero journey.


In addition, Pharmacosmos UK Ltd. is committed to achieving net-zero emissions and has initiatives in place to support this objective at the local level.

Reporting boundary

The scope of emissions covers the entire Pharmacosmos Group, including Pharmacosmos A/S and all affiliates, such as Pharmacosmos UK Ltd. Baseline data reported in relation to the former CRP published in December 2024 only reflected Pharmacosmos UK Ltd.

The organizational boundary and the entities included under Pharmacosmos Group are illustrated below:

Pharmacosmos Group



Methodology

The baseline emissions calculation and reporting for other financial years, is conducted in accordance with the Greenhouse Gas Protocol and the UK Government Procurement Act PPN 006.

All Scope 3 categories for which the Pharmacosmos Group has activities are included in the baseline.

To measure ongoing progress toward reduction targets, a consistent methodology is applied across reporting years. Any updates to data, methodology, or structural changes between reporting years will trigger a recalculation of the base year to ensure emissions can be compared across different financial years.

Baseline emissions footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline year: Financial year 2022/23

Additional details relating to the baseline emissions calculations:

Reporting period

The reporting year covers the period from 1 May 2022 to 30 April 2023.

Emissions profile:

- **Scope 1**
The majority of Scope 1 emissions stem from the consumption of natural gas (both piped gas and LPG) at the production site in Denmark, which is used in the processing and production of products.
- **Scope 2**

Scope 2 emissions stem from electricity consumption, which is used both in production processes and for general office facilities, including computers, lighting, and other equipment. Pharmacosmos group uses the market-based approach to track progress towards targets.

- **Scope 3**

The most significant Scope 3 emissions in the inventory are from categories 1, 2, and 6. The distribution of Scope 3 emissions by category is shown in the table below.

1. Purchased goods and services

Emissions from purchased goods and services stem from a variety of sources. Purchases of raw materials, expenses related to contract manufacturing operators, and similar activities are key contributors to emissions. Service expenses such as events and conferences are also among the main contributors. Emissions are primarily calculated using spend-based data. For raw materials, both average data and supplier-specific reports have been used to calculate emissions.

2. Capital goods

Emissions from capital goods are mainly driven by investments in research and development, clinical trials, and related activities. Construction and maintenance of production facilities also constitute a significant share. All emissions from capital goods are calculated using the spend-based approach.

6. Business travel

Emissions from business travel stem primarily from sales activities across markets and affiliates. Emissions are calculated using distance-based data where possible and otherwise using the spend-based approach.

Baseline year emissions:	
<i>Emissions</i>	<i>Total (tCO2e)</i>
Scope 1	2,099
Scope 2 (Market based)	3,590
Scope 2 (Location based)	820
Scope 3	38,739
1. Purchased goods and services	21,966
2. Capital goods	8,672
3. Fuel- and energy-related activities not in scope 1 & 2	701
4. Upstream transportation	893
5. Waste generated in operations	1,642
6. Business travel	3,473
7. Employee commuting	1,268
9. Downstream transportation	45
12. End of life treatment of sold products	79
10-11; 13-15	No relevant activities
Total emissions	44,428

Current emissions reporting

Reporting year: Financial year 2024/25

2024/25 year emissions:

<i>Emissions</i>	<i>Total (tCO2e)</i>
Scope 1	1,968
Scope 2 (Market based)	3,253
Scope 2 (Location based)	300
Scope 3	41,608
1. Purchased goods and services	20,858
2. Capital goods	11,754
3. Fuel- and energy-related activities not in scope 1 & 2	620
4. Upstream transportation	1,269
5. Waste generated in operations	1,631
6. Business travel	4,196
7. Employee commuting	1,086
9. Downstream transportation	63
12. End of life treatment of sold products	132
10-11; 13-15	<i>No relevant activities</i>
Total emissions	46,829

Emissions reduction targets

To mitigate the impact on climate change, Pharmacosmos Group is committed to achieving Net Zero emissions in 2045 across scope 1, 2 and 3. Moreover, the following near-term targets have been established:

- Reduce absolute scope 1 and 2 emissions by 55% in financial year 2032/33 from our 2022/23 baseline year.
- Engage at least 67% (by emission) of scope 3 suppliers to have science-based targets by financial year 2029/30.

Progress against targets

Scope 1 and 2

As illustrated in the figure below, Scope 1 and 2¹ emissions have decreased by 8% since the base year. A linear trajectory towards the near-term targets corresponds to a 5.5% absolute reduction per year, meaning there is a gap of approximately 3% between the achieved reduction and the target trajectory in 2024/25. However, with the planned carbon reduction initiatives, the Pharmacosmos group is expected to achieve at least a 38.5% in 2029/30 compared to the base year, thereby aligning fully with the trajectory.

All realised and projected emissions reductions shown in the graph below are presented in absolute tonnes of CO₂e and does not include off-sets².




Figure 1 – The figure illustrates achieved reductions, as well as targets, and the corresponding trajectory. It demonstrates Pharmacosmos Groups progress towards target.

Scope 3


¹ The market-based approach is used to track progress towards target.

² The Pharmacosmos Group is monitoring the ongoing revision of the Net-Zero Standard and will adjust its long-term targets accordingly. Currently, it is expected that 10% of the net-zero target for 2045 can be achieved through offsets, in accordance with the SBTi standard. 90% shall be absolute reductions.

Pharmacosmos Group is also committed to reaching net zero in Scope 3. Currently, 80% of Scope 3 emissions are calculated based on spend, making it difficult to track reduction efforts in absolute tonnes of CO₂e. For this reason, Pharmacosmos group has put in place a near-term target for the share of suppliers with Science Based Targets. By doing so, Pharmacosmos can implement reduction efforts throughout the value chain while improving data accuracy to track and monitor how these initiatives reduce absolute tonnes of CO₂e.

In 2024/25, it is estimated that 33% of suppliers (by emission), have set Science-Based Targets³. The target is to reach 67% by 2029/30.

From 2022/23 to 2024/25 there is a growth in scope 3 emissions at 7.4 %, mainly driven by growth and an increase in expenditure.



Carbon reduction projects

Completed carbon reduction initiatives

1. **Electrification of production equipment:** Pharmacosmos group is replacing the existing drying equipment running on LPG, with drying equipment running on electricity. This equates to roughly 5-10 % of scope 1 emissions. Transitioning from natural gas to electricity will reduce Scope 1 emissions and temporarily increase Scope 2. However, scope 2 emissions will be addressed through market-based instruments (see future carbon reduction initiatives). The project is expected to be completed in 2026.

Pharmacosmos UK Ltd. accounts for only a limited share of the total Pharmacosmos Group emissions, as production takes place at Parent company level in Holbæk, Denmark, while Pharmacosmos UK Ltd. is responsible for the sales and distribution of products.

However, measures targeting emissions from the production process (as the above mentioned), will have an impact on Pharmacosmos UK Ltd., contributing to a portfolio of more carbon-efficient products on the UK market.

³ SBTi database is used for estimation of share of suppliers. In the initial screening, coverage is estimated by using spend as a proxy.

2. In addition, Pharmacosmos UK Ltd. has implemented the following local initiatives at its sales and distribution office:

2.1 Employee Commuting and Travel Survey: Among a sample of employees, a survey was conducted in 2023/24 to assess vehicle type for commuting and travel. It showed that approximately 18% of employees used either electric or hybrid cars. In a recent vehicle review from January 2026, we have found that 29.5 % of current employees are driving either Electrical vehicle or hybrid cars.

2.2 Electric Vehicle (EV) Scheme: A salary sacrifice EV scheme was made available in 2024/25. In 2025/26 we will extend this initiative with the introduction of a second scheme.

2.3 Cycle-to-Work Scheme: A cycle-to-work campaign was introduced in (2025/26) to promote cycling as a sustainable commuting option.

2.4 Travel Management System: An update to the methodology for estimating emissions from business travel was implemented in 2024/25. Through Pharmacosmos UK Ltd.'s reporting system ("Concur"), travel distances and modes of transport can now be tracked more precisely, enabling activity-based calculations and improved identification and tracking of reduction initiatives

2.5 Office Refurbishment: During 2025/26 an office refurbishment was undertaken, which included installation of waste recycling system and motion sensitive light switches in various meeting rooms

Future carbon reduction initiatives

1. Submitting to Science Based Targets initiative: Pharmacosmos Group are currently in the process of formalising its near-term targets by preparing submission to the Science Based Targets initiative (SBTi). As part of this work, several concrete emission-reduction levers are being assessed. The most important of these are listed in the initiatives below.
2. Investment in Power Purchase Agreements (PPAs): Pharmacosmos Group is currently examining opportunities to invest in Power Purchase Agreements (PPAs) for renewable electricity. As electricity consumption is a significant contributor to the total Scope 1 + 2 emissions, investment in PPAs represents an important reduction lever for the Pharmacosmos Group. Furthermore, as production processes are increasingly electrified, the relevance of this lever will continue to grow. Pharmacosmos group aims to invest in PPAs with strong additionality.
3. Electrification of production processes: Today, natural gas accounts for approximately 65% of energy sources consumption at its production facilities in Denmark. It is being examined how these processes can be electrified to reduce emissions from Pharmacosmos' fuel consumption.
4. Supplier programme: In addressing the near-term Scope 3 target, an approach toward suppliers to encourage commitment to the SBTi, is being developed.

Declaration and sign off

This Carbon Reduction Plan has been completed in accordance with PPN 006 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹³ and uses the appropriate government emission conversion factors for greenhouse gas company reporting.¹⁴

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements (where required), and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.¹⁵

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the supplier:



.....
Executive Vice President, Steen Sogaard

Date: 17 FEBRUARY 2026

¹³ <https://ghgprotocol.org/corporate-standard>

¹⁴ www.gov.uk/government/collections/government-conversion-factors-for-company-reporting

¹⁵ <https://ghgprotocol.org/standards/scope-3-standard>